Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

Chronic lymphocytic leukemia (CLL) is characterized by the peripheral accumulation of neoplastic B cells and is frequently complicated by the systemic immunosuppression associated with an impairment in B and T lymphocyte activation. We hypothesized that the expression of immune checkpoint suppressor...

Full description

Saved in:

Bibliographic Details
Main Authors:	L. Karabon, A. Partyka, L. Ciszak, E. Pawlak-Adamska, A. Tomkiewicz, A. Bojarska-Junak, J. Roliński, D. Wołowiec, T. Wrobel, I. Frydecka, A. Kosmaczewska
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2020/6545921
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Upper Respiratory Tract Colonization by Gram-Negative Rods in Patients with Chronic Lymphocytic Leukemia: Analysis of Risk Factors
by: Izabela Korona-Glowniak, et al.
Published: (2012-01-01)

Association of Soluble Immune Checkpoint Molecules PD1 and 4‐1BB With CTLA‐4Ig Treatment Response in Early Rheumatoid Arthritis
by: Tilia Selldén, et al.
Published: (2025-07-01)

Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-γ-Secreting Cells, Especially in Patients with Clinical Complications
by: Agata Kosmaczewska, et al.
Published: (2020-01-01)

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice
by: William Stohl, et al.
Published: (2019-12-01)

Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
by: Wojciech Krajewski, et al.
Published: (2020-04-01)

BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes
by: Muhammad Zainul Arifin, et al.
Published: (2025-02-01)

The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure
by: Shoulian Huang, et al.
Published: (2025-04-01)

TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia
by: Mashael Alqahtani, et al.
Published: (2024-12-01)

MLR Corresponds to the Functional Status of Monocytes in Chronic Lymphocytic Leukemia
by: Wioleta Grzegorzewska, et al.
Published: (2025-01-01)

Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer
by: Jiawei Guan, et al.
Published: (2023-12-01)

Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro
by: Ilaria Cosci, et al.
Published: (2025-03-01)

BTLA agonist attenuates Th17-driven inflammation in a mouse model of steroid-resistant asthma
by: Christine Quach, et al.
Published: (2025-03-01)

Bioengineering Platelets Presenting PD‐L1, Galectin‐9 and BTLA to Ameliorate Type 1 Diabetes
by: Yumeng Ma, et al.
Published: (2025-04-01)

Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients
by: Jiayu Liu, et al.
Published: (2018-01-01)

The BTLA and PD‐1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells
by: Hyun J. Hwang, et al.
Published: (2021-03-01)

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients
by: Lucie Aubergeon, et al.
Published: (2024-12-01)

Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms
by: T. V. Glazanova, et al.
Published: (2025-01-01)

Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency
by: T. W. Hoffman, et al.
Published: (2023-01-01)

Immune checkpoint PD-1/PD-L1 CTLA-4/CD80 are blocked by Rhus verniciflua stokes and its active compounds
by: Tae In Kim, et al.
Published: (2020-01-01)

Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications
by: Erfan Rezazadeh‐Gavgani, et al.
Published: (2025-04-01)

Distinct characteristics of BTLA/HVEM axis expression on Tregs and its impact on the expansion and attributes of Tregs in patients with active pulmonary tuberculosis
by: Peijun Tang, et al.
Published: (2024-09-01)

EVALUATION OF THE CONTENT OF CD4+CD25+CD127LOW REGULATORY T CELLS AND THEIR FUNCTIONAL STATUS ACCORDING TO THE EXPRESSION OF CTLA-4 AND CD39 MOLECULES IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: G. A. Zhulai, et al.
Published: (2014-06-01)

Prognostic value of the levels of CTLA-4 and its ligand B7.2 in patients with colorectal cancer
by: A. V. Chetveryakov, et al.
Published: (2023-07-01)

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
by: Rubén Martín-Escolano, et al.
Published: (2024-10-01)

Comparison of the intracellular trafficking itinerary of ctla-4 orthologues.
by: Satdip Kaur, et al.
Published: (2013-01-01)

Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2025
by: Iwona Hus, et al.
Published: (2025-01-01)

The effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency
by: Sara Posadas-Cantera, et al.
Published: (2025-01-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01)

CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis
by: Minjun Ahn, et al.
Published: (2025-05-01)

Checkpoint Inhibitor Myocarditis–Mediated Conduction Abnormalities Reversed With Early Intravenous Steroid Administration: A Case Report
by: Andrew S. Baird, et al.
Published: (2024-07-01)

Anthropometric parameters in patients with ischemic myocardial dilation and CTLA4 rs231775 polymorphisms
by: Oksana O. Kuznetsova, et al.
Published: (2025-01-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

Systematic regulation of immune checkpoint molecules by redox regulators CNC-bZIP transcription factors
by: Haoming Ning, et al.
Published: (2024-11-01)

An African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans.
by: James M Kelley, et al.
Published: (2009-03-01)

Correlation of TSHR and CTLA-4 Single Nucleotide Polymorphisms with Graves Disease
by: Weihua Sun, et al.
Published: (2019-01-01)

β-Catenin: A Key Molecule in Osteoblast Differentiation
by: Edyta Wróbel, et al.
Published: (2025-07-01)

Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia
by: Armin Dozandeh-Jouybari, et al.
Published: (2025-06-01)

An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity
by: Li Xiao, et al.
Published: (2025-07-01)

Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
by: Lawrence Fong, et al.
Published: (2025-04-01)